We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PerkinElmer and Cerep Announce Expansion of Kinase Assay Offerings
News

PerkinElmer and Cerep Announce Expansion of Kinase Assay Offerings

PerkinElmer and Cerep Announce Expansion of Kinase Assay Offerings
News

PerkinElmer and Cerep Announce Expansion of Kinase Assay Offerings

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PerkinElmer and Cerep Announce Expansion of Kinase Assay Offerings"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

At the 15th Annual Society for Biomolecular Sciences (SBS) Conference, PerkinElmer, Inc. announced the expansion of their kinase assay offering. Close to 200 new kinase assays validated with PerkinElmer’s LANCE® Ultra™ technology will be offered for use through Cerep’s drug candidates selection and qualification services.

The collaboration between the two companies first announced in April 2008 delivers custom drug discovery services, through a combination of PerkinElmer’s leading assay technologies, and Cerep’s target screening and drug discovery offerings. Key therapeutic research pathways supported by the new 189 kinase assays include cancer, cardiac disease, central nervous system disorders, inflammation, diabetes, and metabolic disorders, amongst others.

“The extensive range of high quality kinase assays now available for screening and profiling through this collaboration is a compelling complement to the profiling services offered by Cerep. It provides our customers with the expansive range of products and expertise necessary for broad compound screening campaigns to aid their research,” said Richard M. Eglen, PhD, president, Bio-discovery, PerkinElmer.

“Our clients can now benefit from testing their compounds against a broad range of kinase targets via a single platform, validated for performance with PerkinElmer’s innovative LANCE Ultra portfolio and diversified Ulight™ substrates, for consistently high quality results.”

The collaboration with Cerep provides PerkinElmer customers with an option to work with a single vendor throughout the entire drug discovery process. Cerep customers in turn have access to several key assay development and detection platforms from PerkinElmer’s Bio-discovery business, including AlphaScreen®, AlphaLISA®, LANCE®, LANCE® Ultra™ and radioligand binding assays for G protein-coupled receptor (GPCR) and kinase assay development.
Advertisement